Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 5/20 | 0.38 |
| ▸ | OGA | O60502 | 5/20 | 0.36 |
| ▸ | BTK | Q06187 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.34 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | THPO | P40225 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23704126 | 0.82 | GRM5 (0.39) | GRM5OGABTKNPC1RAB9A | |
| SCHEMBL6861227 | 0.81 | GRM5 (0.42) | GRM5NPC1RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL6320562 | 0.80 | KDM4E (0.36) | GRM5NPC1RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL21827566 | 0.80 | MAPK8 (0.43) | GRM5BTKNPC1RAB9AALDH1A1 | |
| SCHEMBL31471018 | 0.80 | MAPK8 (0.43) | GRM5BTKNPC1RAB9AALDH1A1 | |
| SCHEMBL31546695 | 0.80 | GRM5 (0.35) | GRM5NPC1RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL10563916 | 0.79 | F2 (0.39) | GRM5NPC1RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL31546840 | 0.79 | GRM5 (0.35) | GRM5NPC1RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL31546688 | 0.78 | SLC6A2 (0.35) | GRM5OGANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL31015422 | 0.77 | CYP11B2 (0.34) | GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210009557-A1 | ACYCLIC CXCR4 INHIBITORS AND USES THEREOF | X4 PHARMACEUTICALS, INC. | 2021-01-14 | — | — | US | disclosed |
| US-20090093512-A1 | 1, 2, 3, 3A, 8, 8A-HEXAHYDRO-2, 7A-DIADA-CYCLOPENTA[A]INDEN-7-ONE DERIVATIVES WHICH BIND TO NEURONAL NICOTINIC ACETYLCHOLINE SPECIFIC RECEPTOR SITES AND ARE USEFUL IN MODULATING CHOLINERGIC FUNCTION AND IN THE TREATMENT OF ADDICTIVE DISORDERS | PFIZER INC | 2009-04-09 | — | — | US | disclosed |
| US-20090093512-A1 | 1, 2, 3, 3A, 8, 8A-HEXAHYDRO-2, 7A-DIADA-CYCLOPENTA[A]INDEN-7-ONE DERIVATIVES WHICH BIND TO NEURONAL NICOTINIC ACETYLCHOLINE SPECIFIC RECEPTOR SITES AND ARE USEFUL IN MODULATING CHOLINERGIC FUNCTION AND IN THE TREATMENT OF ADDICTIVE DISORDERS | PFIZER INC | 2009-04-09 | — | — | US | disclosed |
| EP-1824852-B1 | 1,2,3,3A,8,8A-HEXAHYDRO-2,7A-DIAZA-CYCLOPENTA[A]INDEN-7-ONE DERIVATIVES WHICH BIND TO NEURONAL NICOTINIC ACETYLCHOLINE SPECIFIC RECEPTOR SITES AND ARE USEFUL IN MODULATING CHOLINERGIC FUNCTION AND IN THE TREATMENT OF ADDICTIVE DISORDERS | PFIZER PROD INC (US) | 2008-05-14 | — | — | EP | disclosed |
| EP-1824852-A1 | 1,2,3,3A,8,8A-HEXAHYDRO-2,7A-DIAZA-CYCLOPENTA[A]INDEN-7-ONE DERIVATIVES WHICH BIND TO NEURONAL NICOTINIC ACETYLCHOLINE SPECIFIC RECEPTOR SITES AND ARE USEFUL IN MODULATING CHOLINERGIC FUNCTION AND IN THE TREATMENT OF ADDICTIVE DISORDERS | Pfizer Products Incorporated (US) | 2007-08-29 | — | — | EP | disclosed |
| WO-2006061711-A1 | 1, 2, 3, 3A, 8, 8A-HEXAHYDRO-2, 7A-DIADA-CYCLOPENTA [A] INDEN-7-ONE DERIVATIVES WHICH BIND TO NEURONAL NICOTINIC ACETYLCHOLINE SPECIFIC RECEPTOR SITES AND ARE USEFUL IN MODULATING CHOLINERGIC FUNCTION AND IN THE TREATMENT OF ADDICTIVE DISORDERS | PFIZER PRODUCTS INC. (US) | 2006-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093512-A1 | 1, 2, 3, 3A, 8, 8A-HEXAHYDRO-2, 7A-DIADA-CYCLOPENTA[A]INDEN-7-ONE DERIVATIVES WHICH BIND TO NEURONAL NICOTINIC ACETYLCHOLINE SPECIFIC RECEPTOR SITES AND ARE USEFUL IN MODULATING CHOLINERGIC FUNCTION AND IN THE TREATMENT OF ADDICTIVE DISORDERS | CHRNA7, CHRNA5, CHRNA1 | GRM5 56/4885OGA 3013/4885BTK 3885/4885 |
| US-20210009557-A1 | ACYCLIC CXCR4 INHIBITORS AND USES THEREOF | CXCR4, CXCR3, CXCR1 | GRM5 427/4885OGA 3258/4885BTK 371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.